ReviewClinical drug investigation2019
Rifamycin SV MMX
Review in Clinical drug investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy.Hepatology communications · 2024Trial
- Antibiotic Mechanisms and Resistance: Molecular Insights and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2026Review
- FDA-approved drugs featuring macrocycles or medium-sized rings.Archiv der Pharmazie · 2025Review
- Nanoscaled Discovery of a Shunt Rifamycin fromACS infectious diseases · 2023Article
- Active Clinical Trials in Hepatic Encephalopathy: Something Old, Something New and Something Borrowed.Neurochemical research · 2023Review
- Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review.Gut microbiome (Cambridge, England) · 2022Review
- Development and Research Progress of Anti-Drug Resistant Bacteria Drugs.Infection and drug resistance · 2021Review
- FDA approved antibacterial drugs: 2018-2019.Discoveries (Craiova, Romania) · 2019Review
- Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs.Antibiotics (Basel, Switzerland) · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rifamycin SV MMX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.